1.
Leslie SW, Sajjad H, Kumar S. Genital Warts. [Updated 2023 Mar11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearlsPublishing; 2023 Jan.
2.
Clanner-Engelshofen BM, Marsela E, Engelsberger N, et al.Condylomata acuminata: A retrospective analysis on clinicalcharacteristics and treatment options. Heliyon. 2020;6(3):e03547.
3.
Scheinfeld N, Lehman DS. An evidence-based review of medicaland surgical treatments of genital warts. Dermatol Online J.2006;12:5.
4.
Svare EI, Kjaer SK, Worm AM, et al. Risk factors for genital HPVDNA in men resemble those found in women: A study of maleattendees at a Danish STD clinic. Sex Transm Infect. 2002;78:215-218.
5.
Tyros G, Mastraftsi S, Gregoriou S, Nicolaidou E. Incidenceof anogenital warts: epidemiological risk factors and real-lifeimpact of human papillomavirus vaccination. Int J STD AIDS.2021;32(1):4-13.
6.
Tamer E, Cakmak SK, Ilhan MN, Artuz F. Demographiccharacteristics and risk factors in Turkish patients with anogenitalwarts. J Infect Public Health. 2016;9(5):661-666.
7.
Kaderli R, Schnüriger B, Brügger LE. The impact of smoking onHPV infection and the development of anogenital warts. Int JColorectal Dis. 2014;29(8):899-908.
8.
Banura C, Mirembe FM, Orem J, Mbonye AK, Kasasa S, MbiddeEK. Prevalence, incidence and risk factors for anogenital warts inSub Saharan Africa: a systematic review and metaanalysis. InfectAgent Cancer. 2013;8(1):27.
9.
Thomas R, Steben M, Greenwald Z, et al. Recurrence of HumanPapillomavirus External Genital Wart Infection Among High-RiskAdults in Montréal, Canada. Sex Transm Dis. 2017;44(11):700-706.
10.
Habel LA, Van Den Eeden SK, Sherman KJ, McKnight B,Stergachis A, Daling JR. Risk factors for incident and recurrentcondylomata acuminata among women. A population-basedstudy. Sex Transm Dis. 1998;25(6):285-292.
11.
Zhan M, Tong Z, Chen S, Miao Y, Yang Y. Establishing a predictionmodel for recurrence of condyloma acuminatum. Eur J Med Res.2022;27(1):183.
12.
Giuliano AR, Sirak B, Abrahamsen M, et al. Genital WartRecurrence Among Men Residing in Brazil, Mexico, and theUnited States. J Infect Dis. 2019;219(5):703-710.
13.
Widschwendter A, Böttcher B, Riedl D, et al. Recurrence ofgenitals warts in pre-HPV vaccine era after laser treatment. ArchGynecol Obstet. 2019;300(3):661-668.
14.
Demir A, Guder S. The effects of vitamin B12, vitamin D, ferritinlevel, neutrophil/monocyte ratio and some blood parameters ongenital warts presence, the number of lesions, and recurrencerates. Andrologia. 2021;53(4):e14006.
15.
Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 Europeanguideline for the management of anogenital warts. J Eur AcadDermatol Venereol. 2013;27(3):263-270.
16.
Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment ofexternal genital warts: a randomised clinical trial comparingpodophyllin, cryotherapy, and electrodesiccation. GenitourinMed. 1990;66(1):16-19.
17.
Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% creamapplied daily to treat anogenital warts: combined results fromwomen in two randomized, placebo-controlled studies. Infect DisObstet Gynecol. 2011;2011:806105.